Monograph
P01CX04 - Miltefosine |
Not porphyrinogenic |
NP |
Rationale
Topical preparation. No significant hepatic exposure. No data pointing to CYP-affinity.
Chemical description
Miltefosine is an aliphatic long chain trimethylammonium derivative related to cell membrane phospholipid components.
Therapeutic characteristics
Miltefosine is a topical antineoplastic agent used as liniment for skin infiltrates connected with mammary cancer, where other treatment has showed to be without effect.
Hepatic exposure
Not significant
Metabolism and pharmacokinetics
No significant systemic exposure. No measurable plasma concentrations of miltefosine after 146 days of epicutaneous administration. No interactions with metabolism of other drugs observed. Not listed as CYP-substrate, or CYP-inducer/inhibitor.
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | Sweetman SC, editor. Martindale: The complete drug reference. Miltefosine. Pharmaceutical Press 2009.
|
|
| * | Other sources | |
| 2. | Swedish National Formulary. FASS. Miltex, Baxter. www.fass.se (product leaflet).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Norway© NAPOS 2024